Richard Wnek

517 total citations
14 papers, 284 citations indexed

About

Richard Wnek is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Richard Wnek has authored 14 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Immunology and 2 papers in Molecular Biology. Recurrent topics in Richard Wnek's work include Immunotherapy and Immune Responses (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and T-cell and B-cell Immunology (4 papers). Richard Wnek is often cited by papers focused on Immunotherapy and Immune Responses (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and T-cell and B-cell Immunology (4 papers). Richard Wnek collaborates with scholars based in United States, Australia and Israel. Richard Wnek's co-authors include Konstantin Dobrenkov, Elliot Chartash, Georgina V. Long, Karen A. Autio, Talia Golan, Kyriakos P. Papadopoulos, Ravit Geva, Kapil Mayawala, Mark Voskoboynik and Kashmira Shah and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Richard Wnek

14 papers receiving 271 citations

Peers

Countries citing papers authored by Richard Wnek

Since Specialization

Citations

This map shows the geographic impact of Richard Wnek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Wnek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Wnek more than expected).

Fields of papers citing papers by Richard Wnek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Wnek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Wnek. The network helps show where Richard Wnek may publish in the future.

Co-authorship network of co-authors of Richard Wnek

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Wnek. A scholar is included among the top collaborators of Richard Wnek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Wnek. Richard Wnek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors 2020 ·Clinical Cancer Research ·Kyriakos P. Papadopoulos, Karen A. Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, (unknown), Richard Wnek, Georgina V. Long	46
2	First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors 2020 ·Cancer ·Ravit Geva, Mark Voskoboynik, Konstantin Dobrenkov, Kapil Mayawala, (unknown), Richard Wnek, Elliot Chartash, Georgina V. Long	47
3	Analytical performance of a 25‐marker spectral cytometry immune monitoring assay in peripheral blood 2020 ·Cytometry Part A ·(unknown), Richard Wnek	8
4	O83 Phase 1 study of an anti-CD27 agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors 2020 ·Oral Presentations ·Ronnie Shapira‐Frommer, (unknown), Konstantin Dobrenkov, Elliot Chartash, Fang Liu, (unknown), Richard Wnek, Manish R. Patel	5
5	Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors. 2019 ·Journal of Clinical Oncology ·Kyriakos P. Papadopoulos, Karen A. Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, Xiaoyun Li, Richard Wnek, Georgina V. Long	18
6	A Preliminary Study for the Assessment of PD-L1 and PD-L2 on Circulating Tumor Cells by Microfluidic-Based Chipcytometry 2017 ·Future Science OA ·(unknown), (unknown), (unknown), (unknown), (unknown), Lewis Z. Hong, Richard Wnek, Yoon Sim Yap, (unknown), Ali Asgar S. Bhagat, Chih‐Liang Chin, (unknown)	16
7	Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses. 2017 ·Journal of Clinical Oncology ·Enrique M. Ocio, María‐Victoria Mateos, Robert Z. Orlowski, David S. Siegel, Donna Reece, Philippe Moreau, Paula Rodríguez‐Otero, Nikhil C. Munshi, David Avigan, Razi Ghori, Richard Wnek, Robin Mogg, Patricia Marinello, Jesús F. San Miguel	10
8	Induction studies with Escherichia coli expressing recombinant interleukin-13 using multi-parameter flow cytometry 2009 ·Biotechnology Letters ·(unknown), John M. Woodley, Richard Wnek, Michel Chartrain, Christopher J. Hewitt	7
9	Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist 2009 ·Journal of Immunological Methods ·Thomas Wısnıewskı, E K Bayne, (unknown), Qing Shao, Richard Wnek, (unknown), Paul Fischer, M J Forrest, Laurence B. Peterson, Xuelei S. Song, (unknown), Julie A. DeMartino, (unknown)	21
10	Characterization of the NOD/scid-[Tg]DR1 mouse expressing HLA-DRB1∗01 transgene: a model of SCID-hu mouse for vaccine development 2007 ·Experimental Hematology ·Ramon E. Camacho, Richard Wnek, Paul Fischer, Kashmira Shah, Dennis M. Zaller, Andrea Woods, Nicola La Monica, Luigi Aurisicchio, Patricia Fitzgerald‐Bocarsly, Gloria C. Koo	11
11	Development of a Highly Productive and Scalable Plasmid DNA Production Platform 2006 ·Biotechnology Progress ·(unknown), (unknown), (unknown), (unknown), Richard Wnek, (unknown), Beth Junker, David K. Robinson, Peter Salmon, Michel Chartrain	33
12	Intra-thymic/splenic engraftment of human T cells in HLA-DR1 transgenic NOD/scid mice 2004 ·Cellular Immunology ·Ramon E. Camacho, Richard Wnek, Kashmira Shah, Dennis M. Zaller, Richard J. O’Reilly, Nancy Collins, Patricia Fitzgerald‐Bocarsly, Gloria C. Koo	9
13	A Small Molecule Very Late Antigen–4 Antagonist Can Inhibit Ovalbumin-induced Lung Inflammation 2003 ·American Journal of Respiratory and Critical Care Medicine ·Gloria C. Koo, Kashmira Shah, G J Ding, Jianying Xiao, Richard Wnek, George Doherty, Xin Tong, R. Blake Pepinsky, Ko‐Chung Lin, William K. Hagmann, D W Kawka, Irwin Singer	36
14	Functional Expression and Characterization of Macaque C-C Chemokine Receptor 3 (CCR3) and Generation of Potent Antagonistic Anti-macaque CCR3 Monoclonal Antibodies 2002 ·Journal of Biological Chemistry ·Liwen Zhang, (unknown), (unknown), (unknown), Richard Wnek, Kristine Johnson, (unknown), Susan A. Iliff, John S. Mudgett, Martin S. Springer, Bruce L. Daugherty	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact